The Rise of Direct-to-Consumer Platforms in Pharma: How, Why Now, What’s Next?
Health is Trending
It is an accepted truism that COVID-19 boosted the adoption of telemedicine and digital health solutions. In a time of everything-from-home, consumers became accustomed to receiving healthcare services and products without in-person visits. But five years later, we see an unexpected extension of that conditioned behavior in what’s always been considered a highly regulated environment: pharmaceutical sales.
At the same time, the world is experiencing a wave of health consciousness bigger than ever before. Patients are more engaged in their health; they’re doing their own research and seeking solutions that meet their complex needs. They’re thinking beyond just what medications they take – crafting treatment plans and health routines conducive to their lifestyles. And perhaps most surprisingly, they’re calling for increased communication and a closed feedback loop, paying closer attention to real-time insight and long-term results.
Pharmaceutical companies are adapting to this permanent behavior shift. Many (the smart ones) are leaning into direct-to-consumer (DTC) care models and the highly technical platforms that support them. Let’s examine the why and how behind pharma’s DTC growth.
Driving the Shift in Big Pharma
DTC models are the next wave for efficiency across the healthcare lifecycle. They promise a simplified, streamlined and empowering healthcare experience for patients, and select benefits for the companies that implement them. Several trends and factors are contributing to the rapid growth of DTC strategies in the pharmaceutical sector:
Compounds & Counterfeits
Companies offering compounded versions of prescription drugs are seeing significant growth, bypassing traditional retail pharmacy models. This alternative for patients has applied direct pressure to those whose drugs are distributed via a more traditional care pathway. A direct channel to consumers can also help large pharmaceutical companies ensure patients receive original products without the risk of counterfeit medications or even generic alternatives that might not be as effective or familiar to the user.
Changing Regulatory Landscape
Regulatory changes around telemedicine are opening new opportunities for pharma companies to sell medications directly to consumers, allowing online consultations and prescriptions. The FDA has even provided clearer guidance on how pharmaceutical products can be advertised online, enabling compliant digital marketing and consumer engagement. Tangentially, more medications are being reclassified from prescription-only to over-the-counter (OTC), making them easier to sell directly.
Better Customer Insights
Consumers increasingly expect customized healthcare solutions tailored to their specific needs and lifestyles. DTC models allow pharma companies to learn directly from patients, offering critical insights into consumer needs and behaviors. Insights gleaned from DTC interactions can drive innovation by pinpointing unmet needs, allowing companies to develop new formulations, dosages or product categories based on patient demands.
Advertising Opportunities
Advances in digital advertising and social media have enabled companies to market directly to consumers in targeted ways. Platforms like Facebook, Instagram and Google allow pharma companies to segment users by behaviors, demographics and interests to promote their offerings and better match patients with the medications and solutions best suited for them.
Cost Reduction & Streamlined Supply Chain
DTC models can eliminate middlemen (e.g., wholesalers and pharmacies), allowing pharma companies to potentially reduce costs. Direct sales often support streamlined supply chains and packaging, reducing waste and environmental impact compared to traditional distribution models. By selling directly, companies may also capture better margins and reinvest in customer acquisition strategies, product improvements, etc.
Stronger ESG Frameworks
Targeted engagement with consumers enhances pharma’s alignment with sustainable and ethical health outcomes. By engaging directly with consumers, pharma companies can better tailor solutions to underserved populations or even remove barriers to healthcare access, such as geographic and logistical limitations. DTC engagement allows pharma companies to communicate directly with consumers about product safety, efficacy and sourcing, reinforcing trust and ethical standards.
Innovation Backed by Technology
Tech advancements are bridging the gap between pharmaceutical innovation and home healthcare delivery, making it easier for companies to connect with patients in a meaningful way.
- Cloud Computing: Scalable and secure cloud platforms provide real-time data access that enables telehealth services, digital pharmacies, remote patient monitoring and heightened collaboration between providers and patients.
- Data and Analytics: Large health data sets are used to track consumer behavior, predict health trends and offer personalized treatments that improve outcomes.
- Artificial Intelligence (AI): AI-powered tools like chatbots, medication reminders and health assistants, enhance patient involvement and adherence to treatment. AI also provides predictive insights, enabling early risk detection and intervention.
- Cybersecurity: Digital platforms require robust cybersecurity measures to protect patient data, maintain regulatory compliance and build trust in technology-driven healthcare solutions.
- eCommerce and Digital Sales Channels: Online platforms and subscription models make it easy for patients to order medications directly, improve accessibility and give companies deeper insights into consumer needs.
What’s Next?
Looking ahead, DTC growth will likely continue in lifestyle-driven categories such as weight loss, sexual dysfunction, migraines, sleep disorders and mental health. These areas often rely on diagnostics like virtual health assessments and online surveys, making them prime opportunities for pharma companies to connect directly with consumers.
Regardless of specialty area, pharma companies must prepare for their DTC delivery by investing in robust, connected ecosystems that support:
- Data-Driven Care: Integrating metrics from prescriptions, devices, lifestyle apps and long-term activity into seamless dashboards for patients and providers.
- Adverse Event Monitoring: Building systems to address patient safety proactively as the traditional safeguards of PCPs and pharmacies evolve.
- Patient Education: Empowering individuals to use DTC platforms effectively while setting realistic expectations of outcomes.
Above all, their platforms must deliver seamless, secure and user-friendly experiences while maintaining compliance with regulatory standards and inclusion of additional clinical protocols.
DTC Do’s and Don’ts
Implementing a DTC model as a large pharmaceutical company offers huge potential — but also significant risk. Success requires more than simply standing up a website; it demands a thoughtful approach to trust, compliance and experience. Here are a few do’s and don’ts to keep in mind.
Do – Empower the Customer:
Provide them with relevant information in a timely manner. For example, how long will it take for their script to be filled after a doctor’s appointment?
Don’t – Talk About Illness to Wellness:
Well, do talk about it, but then execute! Make it real through functions and features that allow users to see their health as a dynamic spectrum, understand where they are today and visualize where they’re going.
Do – Address Adherence:
Systems that are integrated, connected and inject a little fun are most likely to be met with success. Avoid over- and under-communicating with real-time insight into usage.
Don’t – Crowd the Customer:
Multiple apps or devices (or worse, log-in screens) will lose the consumer’s interest. Keep it simple, keep them engaged.
Do – Learn from eCommerce Disruption:
It is not a question of if, but when, online and/or mail prescriptions overtake pharmacy counter visits. Organizations that fail to adapt their models now risk being left behind by faster, more convenient alternatives.
Pharma’s direct-to-consumer shift is not a choice — it’s a new reality. Consumers demand more from the system than ever before. They want convenience and transparency in care, allowing them to realize the true benefits. Some they’ll see and some they won’t. But lower drug costs, better medication adherence and improved patient engagement are all possible with the customer at the center of care.
Done right, DTC models can define the future of the industry. Engage with EPAM’s Life Sciences & Healthcare team to learn more.
